Citations

Clear

2511 citation(s) found for "Yang, Yu".

Development and validation of an artificial intelligence–based deep learning imaging model for early lung cancer detection: DAVINCI, a retrospective study of 8,962 patients.
Noor-Ain, Syeda Hafsa, Khan, R, Ajay, Gadugoyyala Guna Sri Phani, Shafi, Nimra, Ramteke, Harshawardhan, Nawaz, Zahra, Gandhi, Sangeetha, Khan, Ifrah, Junnuthula, Akshaya, Murugavel, Dineshbaba, Rapaka, Divya Sree, Ramagiri, Vishwajeet, Alamy, Haroon , Hazra, Sourav, Ma, Hongwei , Qianyi, Yang, Shafi, Nimra, Ramteke, Harshawardhan, Hazra, Sourav, Ma, Hongwei

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8021-8021

10.1200/jco.2026.44.16_suppl.8021 Get It

8021 Background: Lung cancer is the leading cause of cancer-related mortality worldwide, primarily due to delayed diagnosis and diagnostic variability in histopathological assessment. Advances in deep learning applied to medical imaging offer the potential to enhance early detection accuracy, reduce interobserver variability, and improve diagnostic efficiency in lung cancer. Methods: In this retrospective study, we evaluated DAVINCI using a dataset of 8,962 patients with confirmed lung malignancies. The model utilizes a specialized architecture combining convolutional neural networks (CNNs) and residual blocks to optimize feature extraction from high-resolution pathological slides. Performance was measured via detection accuracy, recall, specificity, and Area Under the Curve (AUC). Results: A total of 8,962 patients were included in the analysis. The DAVINCI model correctly identified lung cancer in 93% of cases, corresponding to 8,334 of 8,962 patients, with a 95% confidence interval (CI) of 86%–100% (7,707–8,962 patients). Model specificity was also 93% (95% CI, 86%–100%), indicating a high true-negative rate. Sensitivity (recall) was 87%, with correct detection in 7,797 patients and a 95% CI of 80%–94% (7,170–8,425 patients). The model demonstrated strong discriminatory performance, achieving an area under the curve (AUC) of 0.91 (95% CI, 0.84–0.98). In comparison, active pathologists achieved a mean diagnostic accuracy of 83%, corresponding to 7,438 of 8,962 cases, with a 95% CI of 76%–90% (6,811–8,066 cases). In terms of efficiency, DAVINCI processed whole-slide images in 16–19 seconds, substantially faster than conventional manual review, which typically requires several minutes per slide. Conclusions: DAVINCI demonstrated superior accuracy, robust discriminatory performance, and markedly faster processing compared with human review, supporting its potential role in early lung cancer detection at scale.
Risk-adapted step-up local therapy for malignant portal vein tumor thrombus from hepatic metastases: A real-world study of microwave ablation with and without iodine-125 seed implantation.
Pham, Hoang Tran , Chun, Li, Bao, Weidong, Tian, Shichao, Zhao, Qingsong, Zhang, Mingyi , Yang, Z Y, Alba, Margarita De, Dong, Zhongyi , Parker, Jefferson , Morecroft, Renee, Elalfy, Aya, COTTLE, CHASEN, Ingram, Demarcus, Abdel-Hakeem, Ahmed, Bains, Shifali, Patel, Parth, Ali, Muhammad, Yang, Vivienne , Pham, Hoang Tran, Morecroft, Renée , Elalfy, Aya, Patel, Parth, Hartzell, Shannon

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4235-4235

10.1200/jco.2026.44.16_suppl.4235 Get It

4235 Background: Malignant portal vein tumor thrombus (PVTT) arising from hepatic metastases is associated with poor prognosis, rapid hepatic decompensation, and limited effective local treatment options despite systemic therapy. In real-world practice, local treatment intensity is frequently adapted to disease burden and treatment response. We evaluated outcomes of a risk-adapted, step-up local treatment strategy using microwave ablation (MWA) alone or in combination with iodine-125 (I-125) seed implantation for patients with malignant PVTT. Methods: We retrospectively reviewed patients with hepatic metastases treated with MWA with or without I-125 seed implantation between 2023 and July 2025. In clinical practice, MWA alone was preferentially used for patients with relatively limited disease burden, while MWA plus I-125 was employed as an escalation strategy for patients with more advanced PVTT or disease progression following MWA alone. The primary endpoint was PVTT-directed local outcome, defined as portal vein patency and/or local control of tumor thrombus on follow-up imaging. Secondary endpoints included progression-free survival (PFS), overall survival (OS), hepatic function changes, and treatment-related toxicity. Survival analyses were considered exploratory. Results: A total of 73 patients were included, of whom 50 were treated with MWA alone and 23 with MWA plus I-125 seed implantation. Patients receiving MWA plus I-125 demonstrated more advanced disease characteristics, including universal presence of PVTT and higher disease stage, consistent with treatment escalation by disease severity. Among patients with PVTT, MWA plus I-125 achieved portal vein patency and/or local control in 65% at first follow-up imaging. Treatment-related toxicities were manageable, with no unexpected grade ≥3 adverse events attributable to I-125 implantation. Median PFS was 11.5 months in patients treated with MWA alone and 9.9 months in patients treated with MWA plus I-125, consistent with greater baseline disease burden in the latter group. Conclusions: MWA alone and MWA plus I-125 function as complementary components of a risk-adapted, step-up local treatment strategy for malignant PVTT from hepatic metastases. Escalation to MWA plus I-125 appears feasible in patients with advanced or refractory PVTT and demonstrates a potential signal for improved PVTT-directed local control and portal vein patency. Prospective studies focused on PVTT-specific endpoints are warranted.
Cohort-level safety and efficacy results for [ 212 Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.
Halfdanarson, Thorvardur Ragnar, Sukrithan, Vineeth, Mancini, Brandon Robert, Mosallaie, Seyed Ali, Balaraman, Savitha, Sibley, Gregory, Starr, Jason S., Anthony, Lowell , Liao, Chih-Yi, Mehr, Samuel, Weiss, J., Ramirez, Robert A., Iravani, Amir Iravani, Baratto, Lucia, Yang, Wenjing, Hanna, Alaa , Keefe, Stephen Michael, Puhlmann, Markus , Prasad, Vikas, Hálfdánarson, Þorvarður R. , Wahl, Richard L. , Sukrithan, Vineeth , Sibley, Gregory S., Starr, Jason S. , Liao, Chih‐Yi , Mehr, Samuel H., Weiss, Jared, Ramirez, Robert A., Keefe, MD Stephen, Prasad, Vikas

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4173-4173

10.1200/jco.2026.44.16_suppl.4173 Get It

4173 Background: [ 212 Pb]VMT-α-NET is an alpha-particle radiation-delivering agent targeted to somatostatin receptor type 2 (SSTR2)-expressing tumors. Here, we present safety and efficacy results from the dose-finding phase 1/2a clinical trial (NCT05636618). Methods: This phase 1/2a dose-escalation study uses a Bayesian algorithm to identify an optimal dose of [ 212 Pb]VMT-α-NET for participants with advanced, well-differentiated NETs expressing SSTR2. Eligible participants must have unresectable or metastatic disease, documented radiologic progression following at least one prior systemic treatment, and evidence of SSTR2 expression (Krenning Score ³2) in ≥1 lesion confirmed on an FDA-approved somatostatin receptor PET scan. Patients previously treated with systemic peptide receptor radionuclide therapy (PRRT) are excluded from enrollment. During the dose-finding phase, participants may receive up to four administrations of [ 212 Pb]VMT-α-NET at their assigned dose level, and they are monitored for dose-limiting toxicities (DLTs) for 42 days and safety throughout the study. Efficacy is evaluated by investigators according to RECIST criteria v1.1. Dosimetry is included as a supportive analysis. Results: As of the 10-Dec-2025 data cut-off (DCO), 56 participants had been enrolled across Cohorts 1, 2, and 3 and received at least one dose of [ 212 Pb]VMT-α-NET: 2 participants in Cohort 1 (2.5 mCi), 46 in Cohort 2 (5 mCi), and 8 in Cohort 3 (6 mCi). No dose-limiting toxicities, grade 5 adverse events, treatment-related discontinuations, serious renal events, dysphagia, or clinically meaningful treatment-related myelosuppression were observed. The median follow-up for all treated participants was 40 weeks (range 6–97). Efficacy has been summarized in this abstract for 25 participants (2 in Cohort 1 and 23 in Cohort 2). Nineteen of these 25 participants remained progression-free at the time of the DCO, with a median efficacy follow-up of 49 weeks (range 6–97). In Cohort 2, investigators observed RECIST v1.1 objective responses in 9 of 23 participants (39%), including 8 confirmed responses. Both participants in Cohort 1 continued to exhibit stable disease after two years of follow-up. Updated safety for all participants and updated efficacy for participants with sufficient maturity beyond the 25 summarized here will be presented at the congress. Conclusions: Treatment with [ 212 Pb]VMT-α-NET continues to demonstrate a favorable safety profile across all treated participants (n = 56) and shows signs of sustained efficacy at the 2.5 mCi and 5 mCi dose levels. The therapy has been well-tolerated with no observed dose-limiting toxicities or serious treatment-related adverse outcomes. Based on these encouraging safety and efficacy findings, the study is ongoing, and enrollment into Cohort 3 (6 mCi) remains active. Clinical trial information: NCT05636618 .
Data from a real-world study: Association of CDCP1 expression level with survival outcomes in mCRC patients treated with bevacizumab or cetuximab plus chemotherapy.
Goretsky, Yitzhar Efraim, Yang, Yan, Bartolini, Michela, Soni, Shivani, Mittal, Pooja, Torres-Gonzalez, Lesly, Shah, Unnati Hemant, Ho-Lo, Jae, Trujillo, Steve Soto , Zhang, Wu, Venook, Alan P., Algaze, Sandra, Millstein, Joshua , Lenz, Heinz-Josef, Torres‐Gonzalez, Lesly , Goretsky, Yitzhar, Yang, Yan , Bartolini, Michela, Soni, Shivani , Mittal, Pooja, Ou, Fang‐Shu , Lo, Jae Ho, Venook, Alan P. , Algaze, Sandra , Lenz, Heinz‐Josef

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3593-3593

10.1200/jco.2026.44.16_suppl.3593 Get It

3593 Background: CUB domain-containing protein 1 (CDCP1) is a transmembrane protein shown to be over-expressed in colorectal cancer (CRC), with an important role in tumor initiation, growth and metastasis. Through interactions with EGFR, CDCP1 promotes nuclear translocation of the key regulators of Wnt signaling, β-catenin and E-cadherin. High CDCP1 expression has been associated with poor survival outcomes in multiple solid tumors but data in CRC remains limited. We investigated associations between CDCP1 level and survival outcomes in patients with metastatic CRC (mCRC) in the phase III clinical trial CALGB/SWOG 80405 (Alliance). Methods: Data from 433 mCRC patients in the CALGB/SWOG 80405 (Alliance) trial were analyzed. Patients received bevacizumab (n = 226) or cetuximab (n = 207) plus chemotherapy as 1st-line treatment. Tumor RNA was extracted from FFPE samples and processed through the HiSeq 2500 (Illumina) platform. Overall survival (OS) and progression free survival (PFS) curves were evaluated in all treatment subgroups and stratified according to high or low CDCP1 expression. Likelihood ratio tests, hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated using Cox proportional hazards multivariate models, adjusting for age, sex, ECOG performance status, tumor location, number of metastatic sites, KRAS status, consensus molecular subtypes, and treatment arm. Results: Overall, low CDCP1 expression was associated with better OS compared to high expression (HR = 1.38; 95% CI 1.07-1.77; 35.8 vs 25.0 months, p = 0.045). Subgroup analysis re-demonstrated this pattern in males (HR = 1.64; 95% CI 1.64-2.28; 35.9 vs 23.6 months, p = 0.01), patients with MSS tumors (HR = 1.56; 95% CI 1.17-2.08; 36.7 vs 25.1 months, p = 0.0094), and patients treated with cetuximab+FOLFOX (HR = 1.79; 95% CI 1.16-2.77; 40.8 vs 24.0 months, p = 0.03). The effect of CDCP1 expression on PFS was less pronounced. Relative to high expression, low expression was associated with better PFS in males (HR = 1.49; 95% CI 1.10-2.03; 13.1 vs 9.8 months, p = 0.027) and left-sided tumors (HR = 1.50; 95% CI 1.10-2.04; 14.4 vs 10.1 months, p = 0.034). Conclusions: Our findings represent real-world data of the predictive role of CDCP1 in patients with mCRC undergoing anti-EGFR or anti-VEGF treatment. Consistent with studies of other cancers, we show that low CDCP1 expression is predictive of better survival outcomes, with subgroup analysis revealing associations in males, MSS tumors, and left-sided tumors. Among treatment groups, low CDCP1 expression is predictive of better OS in cetuximab+FOLFOX-treated patients, a key finding given CDCP1’s close mechanistic ties to EGFR. Further studies should explore whether these associations are seen in other treatment modalities and whether CDCP1 blockade could represent a viable strategy in patients with high expression.
First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in EGFR -mutant ( EGFR m) NSCLC.
Le, Xiuning, Spira, A, Gupta, Divya , Nagasaka, Misako, Riess, Jonathan W., Yang, James Chih Hsin, Rotow, Julia K., Bazhenova, Lyudmila, Li, Molly SC, Izumi, Hiroki, Parikh, K, Hayashi, Hidetoshi, Philipovskiy, Alexander, Kim, Chul, Cui, J. Jean, Zhou, Jihao, Oxnard, Geoff, Zalutskaya, Alena , Horinouchi, Hidehito, Le, Xiuning , Spira, Alexander I. , Nagasaka, Misako , Riess, Jonathan W. , Yang, James Chih‐Hsin , Bazhenova, Lyudmila , Hayashi, Hidetoshi , Philipovskiy, Alexander V. , Johnson, Melissa L. , Cui, J. Jean , Zalutskaya, Alena A. , Horinouchi, Hidehito

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3014-3014

10.1200/jco.2026.44.16_suppl.3014 Get It

3014 Background: Macrocyclic next-generation tyrosine kinase inhibitors (TKIs) have transformed outcomes in ALK- and ROS1-positive NSCLC; such creatively designed medicines are similarly needed to improve outcomes in EGFR-mutant NSCLC. Using a novel, mutant-selective macrocyclic structure, BH-30643 was designed for super-potency against driver EGFRm, largely sparing wildtype (WT) EGFR, and with unique invulnerability to resistance from C797S with or without T790M. Here we report emerging first-in-human dose-escalation data from the SOLARA trial (NCT06706076). Methods: Phase 1 dose escalation used a BOIN design with backfill at potentially efficacious doses. Expansion cohorts targeted populations of interest. Patients (pts) had advanced NSCLC with EGFR and/or HER2 mutations detected on local testing (tissue or plasma). Measurable disease was required; asymptomatic untreated brain metastases (BM) were permitted. Objectives included safety, PK, and RECIST response rate (ORR). Plasma NGS was performed at baseline and on treatment. Results: As of 01/05/2026, 72 pts enrolled into dose escalation and backfill across 7 dose levels at a total daily dose of 20mg -160mg, median age 62, 44% Asian, 65% with history of BM, median of 3 prior lines of treatment (range 1-12). EGFR mutations included classical (38 pts), exon20ins (14 pts) and other/atypical (18 pts) or HER2 mutations (2 pts). Plasma exposures at doses of 40mg BID and above achieved > 10x coverage over target EC90 and exceeded exposure levels of most contemporary EGFR TKIs. Common TRAE ( > 10%) were WT EGFR-associated, including diarrhea (38%), rash (28%), fatigue (15%), stomatitis (13%), and were predominantly grade 1. Bilirubin elevation was seen in 26 pts (36%) related to off-target UGT1A1 inhibition (Gilbert’s-like). Grade 3 TRAE were seen in 15 pts (18%), most commonly bilirubin (8/15); DLTs included bilirubin increase and mucositis, occurring at doses ≥ 60mg BID. No pneumonitis was observed. Responses were observed across diverse EGFRm subsets, including in CNS. Including expansion pts, 28 pts enrolled with C797S on their most recent informative molecular testing (6 with concurrent MET+ or KRAS+), with 23 still on therapy. Of 17 with on-treatment scans, partial responses (confirmed or ongoing) were seen in 10 (59%); ORR was comparable with (50%) or without (66%) T790M. Of 9 pts with baseline C797S detected in ctDNA (3 with T790M), 7 had > 99% reduction of C797S VAF on treatment. Conclusions: Leveraging a novel macrocyclic scaffold, BH-30643 is the first TKI monotherapy to demonstrate clinical responses against C797S both with or without T790M. High plasma exposures combined with super-potency, CNS activity, and favorable safety offers potential for deep and durable EGFR inhibition. Enrollment into backfill and expansion cohorts is ongoing to better characterize activity in both TKI-naïve and resistant pts. Clinical trial information: NCT06706076 .
Long term outcomes of central neurocytoma in a multi-institutional cohort: The role of radiotherapy and Ki-67.
Yang, Y Z, Leenstra, James L. , Wadhwani, Nitin, Ho, Alexander, Brown, P D, Sachdev, Sean, Yang, Yufan, Wadhwani, Nitin R. , Ho, Alexander , Sachdev, Sean

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 2089-2089

10.1200/jco.2026.44.16_suppl.2089 Get It

2089 Background: Central neurocytomas (CNs) are rare, WHO grade 2 brain tumors that can have relatively high recurrence rates following surgical resection. Owing to the rarity of CNs and limited robust data, the optimal use and timing of radiotherapy (RT) remain undefined, particularly in young adults with low mortality. Tumor proliferation index (Ki-67) may also predict CN recurrence rates, but there is no consensus on its utility in clinical practice. The present collaboration between Northwestern University and the Mayo Clinic describes long-term outcomes of CN as it relates to RT timing and Ki-67 level. Methods: Patients established between 1990-2025 with a tissue diagnosis of CN at Northwestern University and the Mayo Clinic were reviewed. Demographic, treatment, and tumor characteristics (histologic/molecular) were recorded. Recurrence free survival (RFS) and overall survival (OS) were calculated according to the Kaplan Meier-method. Results: Fifty-one patients with CN (51% male, 49% female)--with a median age of 26 years and 9.7 years median follow-up--were included. RFS at 2, 5, and 10 years for the cohort was 79%, 65%, and 59% respectively; OS at 10 years for the cohort was 94%, and no deaths were attributed to uncontrolled CN. Subtotal resection (STR) yielded 2- and 5-year RFS of 74% and 65%, while gross total resection (GTR) yielded 2- and 5-year RFS of 90% and 66%. Median Ki-67 of the cohort was 3%; RFS at 2 and 5 years for Ki-67 <3% was 82% and 76%, compared to 76% and 43% for Ki-67 ≥3% (p<0.02). In patients who underwent resection without adjuvant RT (n=35), those with STR had a 2- and 5-year RFS of 61% and 45%, and those with GTR had a 2- and 5- year RFS of 88% and 61%. Additionally, without adjuvant RT, RFS at 2 and 5 years for Ki-67 <3% was 73% and 64% versus 71% and 24% for Ki-67 ≥3%. Among patients without adjuvant RT and Ki-67 ≥3% (n=14), 2-year RFS was 60% after STR and 78% after GTR. Salvage RT after first recurrence (n=16) had a 5-year RFS of 81%, with a median follow-up of 4.1 years. Conclusions: We report one of the largest cohorts of CN with long-term follow-up. STR and/or Ki-67 ≥3% were associated with shorter RFS. Salvage RT at recurrence achieved durable long-term tumor control, and long-term (~10-year) mortality was low. In appropriately selected patients, observation after resection may be a reasonable initial strategy, with RT reserved for salvage. General cohort characteristics (n=51) with Ki-67 (n=39). Variable Number (%) Median Age (years) 26 (range: 5-57) Gender, Male:Female (M/F) 26:25 (51/49) Subtotal Resection 29 (57) Gross Total Resection 22 (43) Adjuvant Radiotherapy 16 (31) Salvage Radiotherapy 16 (31) No Radiotherapy 19 (38) Ki-67 ≥3 21 (56) Ki-67 <3 18 (44)
Enhanced financial assistance intervention for unmet essential needs: A prospective pilot study to improve timely cancer treatment completion.
Jiang, Shannon Jinxia, Johnson, Kimberly J., Yang, Joanna C. , Barnes, Justin M. , Johnson, Kimberly J., Chino, Fumiko

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 11078-11078

10.1200/jco.2026.44.16_suppl.11078 Get It

11078 Background: Unmet essential needs, such as food, transportation, and housing insecurity, can create barriers to timely cancer treatment. Delayed or prolonged courses of definitive radiotherapy (RT) can compromise cancer outcomes like recurrence and survival. There are limited prospective data testing interventions to improve timely cancer treatment completion by meeting essential needs. Methods: We conducted a pragmatic single-arm pilot study testing an enhanced financial assistance intervention for unmet needs during RT. Eligibility criteria included adults with a cancer diagnosis and unmet social needs (via social risk screening and/or social worker evaluation) who were prescribed or undergoing a course of RT with > 10 fractions remaining. Participants received standard institutional assistance (e.g., limited support for travel/lodging with strict eligibility criteria) plus the enhanced assistance intervention, including needs assessments prior to and during RT and up to $2000/patient of tailored unconditional monetary transfer via gift cards for all essential needs identified. The primary outcome was delay-free completion of RT (DFC: completing all prescribed RT fractions and delaying < 5 fractions). The study was powered (power = 80%, 1-sided alpha = 0.2 for this pilot study) to detect a 10-percentage point increase in % DFC relative to a historic benchmark of 83% (based on similar patients from our institution), with required sample size of N = 33. Due to delays in gift card administration (on average ~2 weeks after consent), we also present per protocol analysis, limited to patients who had > 10 fractions remaining after first receiving financial assistance. Post-hoc analyses using generalized linear mixed models evaluated percentages of delayed fractions prior to and after an individual’s receipt of financial assistance. Results: 35 met inclusion criteria and were approached, 33/35 enrolled. Participants received median assistance of $1800 ($700-2000) and had a median of 27 RT fractions after consent (range: 12-35) and 17 (3-34) after receiving assistance. In the overall cohort, 1 patient did not complete RT and 2 patients had ≥5 delayed fractions, leading to 30/33 achieving DFC (90.9%, 80% CI = 83.9 – 100), significantly higher than the 83% benchmark. In the per protocol analysis, 27/28 achieved DFC (96.4%, 80% CI = 89.7–100, P = .037). Among the 27 patients who started RT prior to receiving assistance, mixed model analysis showed more delayed fractions prior to (7.1%) vs. after (3.0%) receiving assistance (OR 2.84, 95% CI = 1.43-5.80, P = .003). Conclusions: In this prospective pilot study, a tailored enhanced financial assistance intervention for unmet essential needs led to improved delay-free completion of RT over a historic benchmark. Further analysis on patient-reported quality of life and financial toxicity will be reported in the future. Clinical trial information: NCT06582849 .
TBCRC 050: A phase 1b/2 trial of niraparib and trastuzumab in HER2-positive metastatic breast cancer (MBC): Efficacy and correlative analyses.
Stringer-Reasor, Erica , Xin, Haichang , Jones, Kyla, O'Sullivan, Ciara Catherine, Giridhar, Karthik, Dees, Elizabeth Claire , Nanda, Rita, Hunter, Natasha, Clark, Amy S. , Zhang, Jianqing, Krop, Ian E., Lin, Nancy U., Rimawi, Mothaffar, Yang, Eddy S. , Jones, Kyla R, Rocque, Gabrielle B. , O’Sullivan, Ciara C. , Nanda, Rita , Hunter, Natasha B. , Zhang, Jianqing , Wolff, Antonio C. , Krop, Ian E. , Lin, Nancy U.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1056-1056

10.1200/jco.2026.44.16_suppl.1056 Get It

1056 Background: Resistance to HER2-directed therapies remains a major challenge in HER2-positiveMBC. In preclinical models, HER2+ tumors overexpress poly (ADP-ribose) polymerase (PARP), and PARP inhibition induces apoptosis through NF-κB suppression even in the absence of pathogenic mutations in BRCA 1/2 . We evaluated the safety, efficacy, and translational correlates of niraparib combined with trastuzumab in patients (pts) with refractory HER2+ MBC. Methods: This open-label Phase 1b/2 trial (NCT03368729) enrolled pts with HER2+ MBC (IHC 3+ and/or FISH amplified), measurable disease, LVEF ≥50%, and progression on ≥1 prior HER2-targeted therapy; stable CNS disease was allowed. Pts with germline BRCA1/2 mutations or prior PARP inhibitor exposure were excluded. Niraparib 300 mg orally was administered on Days 1–21 of a 21-day cycle with trastuzumab 6 mg/kg IV every 3 weeks (loading dose 8 mg/kg on cycle 1). The Phase 2 portion used a Gehan/Simon two-stage design with early stopping for futility (P0=24%); ≥1 response among the first 20 patients triggered expansion to 40 patients. ORR was assessed by RECIST v1.1, meeting the primary endpoint and allowing response rate estimation with <7% standard error and a two-sided 95% exact CI width of 0.28. Gene expression profiling of paired tumor tissue and peripheral blood mononuclear cells (PBMCs) was performed using the NanoString nCounter Tumor Signaling 360 panel at pretreatment compared to cycle 2. Results: Forty-six pts were enrolled (9/2019–2/2025); 41 were evaluable for response. Pts were heavily pretreated (median 3 prior regimens), including trastuzumab deruxtecan in 22 pts; 33% had brain metastases. Treatment-related adverse events were predominantly grade 1–2 and manageable. Clinical benefit rate (CBR) was 44% (18/41) including 1 complete response, 2 partial responses, and 15 stable disease. Eleven patients achieved disease control ≥ 6 months; 1 patient remained on treatment at data cutoff. Tumor profiling revealed enrichment of a B-cell–driven tertiary lymphoid structure signature with reduced hypoxia signaling in responders. Matched PBMC analyses demonstrated coordinated downregulation of interferon signaling, DNA damage response, metabolic activation, angiogenesis, and resistance pathways in clinical responders, whereas non-responders retained signatures of chronic stress and immune exhaustion. Conclusions: Niraparib plus trastuzumab demonstrated a favorable safety profile and durable clinical benefit in heavily pretreated HER2+ MBC. Integrated tumor and blood-based analyses identify immune-organized tumor microenvironments and systemic immune normalization as key correlates of prolonged response, supporting further investigation of PARP inhibition strategies. Clinical trial information: NCT03368729 .
Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): An in-depth safety analysis of HER2CLIMB-05.
Dieras, V, Curigliano, G, M, Casado Martín, Lerebours, Florence, Tsurutani, Junji , Jerzak, Katarzyna J. , Hu, Xichun, Aquino, Luciana Carla Martins de, O'Sullivan, Ciara Catherine, Tokunaga, Eriko , Okines, Alicia Frances Clare, Huang, Chiun-Sheng, Sohn, J, Cronemberger, Eduardo , Mueller, Volkmar, Kaur, Manjot, Viala, Helene, Yang, Shan, Hamilton, Erika P., Dièras, Véronique , Curigliano, Giuseppe , Lerebours, Florence , Savard, Marie-France , Hu, Xichun , O’Sullivan, Ciara C. , Okines, Alicia , Sohn, Joohyuk

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1042-1042

10.1200/jco.2026.44.16_suppl.1042 Get It

1042 Background: The primary analysis of the phase 3 HER2CLIMB-05 study (NCT05132582) showed the addition of TUC to 1L maintenance HP yielded a statistically significant improvement in progression-free survival (per investigator) versus control treatment (hazard ratio: 0.641, P < 0.0001) in patients with HER2+ MBC. Here we report our findings from an in-depth safety analysis of HER2CLIMB-05. Methods: Patients with centrally confirmed HER2+ MBC without evidence of progression following chemotherapy-based induction treatment (taxane + HP) were randomly assigned 1:1 to TUC (300 mg) or placebo (PBO) BID, both in combination with HP. The safety analysis set included all randomly assigned patients who received ≥1 dose of any study treatment. Treatment-emergent adverse events (TEAEs), laboratory values, and TUC/PBO dose modifications and discontinuations were examined. Results: Among patients in the safety analysis set (TUC arm = 326; PBO arm = 324), median treatment durations of TUC and PBO were 17.1 months (range: 0.4–36.5) and 15.5 months (range: 0.5–41.3), respectively. Grade (G) ≥3 TEAEs occurred in 42.3% of patients in the TUC arm and 24.4% in the PBO arm; the most frequent G ≥3 TEAEs in the TUC arm were elevated alanine aminotransferase (ALT; 13.5%) and aspartate aminotransferase (AST; 7.1%). TUC was discontinued in 13.5% of patients due to a TEAE. Cardiac TEAEs were similar between TUC and PBO arms (4.3% vs 6.2%). TEAEs of hepatic events (43.6% vs 15.7%) and diarrhea (72.7% vs 51.2%) occurred at higher incidence in the TUC arm versus the PBO arm (Table). In the TUC arm, increased ALT (28.2%) and AST (25.8%) accounted for the majority of hepatic TEAEs. Most hepatic and diarrhea TEAEs were managed with TUC dose modifications and/or discontinuation; 7.7% of patients discontinued TUC due to hepatic TEAEs and 1.5% discontinued due to diarrhea (Table). Among the patients with a TEAE of diarrhea, 57.7% and 29.9%, respectively, in the TUC and PBO arms used antidiarrheals; the most used medication was loperamide. Further details of the in-depth safety analysis will be presented. Conclusions: TUC addition to 1L HP maintenance therapy may be an effective option for HER2+ MBC with a clinically manageable safety profile. Clinical trial information: NCT05132582 . TEAEs* Any Any hepatic Increased ALT/AST Diarrhea Arm TUC PBO TUC PBO TUC PBO TUC PBO Any G, % 99.1 96.6 43.6 15.7 28.2/25.8 7.1/9.0 72.7 51.2 G ≥3 42.3 24.4 18.1 1.2 13.5/7.1 0.6/0.6 6.1 4.0 Any G: Median time to onset (days) 34.5 85.0 11.0 32.0 Median time to resolution (days) 25.0 22.0 2.0 5.0 Any G: TUC/PBO dose hold, % 49.4 25.3 19.3 2.5 12.6/4.0 0.6/0.6 8.6 3.4 TUC/PBO dose reduction, % 29.1 11.1 16.3 0.9 11.7/2.8 0.3/0.6 6.4 3.1 TUC/PBO discontinuation, % 13.5 2.2 7.7 0 4.0/0.3 0/0 1.5 0.9 *As of data cutoff, Sep 5, 2025.
Secretion of the HBV small surface antigen is driven by an ER autophagic pathway
Cao, Hong, Krueger, Eugene, Chen, Jing, Yang, Huiling, Chia, Jia Jun , Beran, Rudolf K, Tam, Jane, Kornyeyev, Dmytro, Holdorf, Meghan , McNiven, Mark A., Krueger, Eugene W. , Chen, Jing, Beran, Rudolf K., Kornyeyev, Dmytro , McNiven, Mark A.

Mayo Clinic

Hepatology Communications | May 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1097/hc9.0000000000000939 | PMID 42172500 Get It

Chronic hepatitis B (CHB), a major global public health burden, is characterized by the presence of high circulating levels of non-infectious subviral particles (SVPs). These SVPs are mainly composed of small hepatitis B surface antigen (SHBs) and are associated with a dysfunctional HBV-specific immune response. Previous studies exploring the cellular mechanisms and molecular pathways by which SVPs are secreted from hepatocytes have utilized either non-hepatic cells or whole-genome HBV-integrated hepatoma cell lines in which SHBs can also be secreted as a component of the virion envelope. In this study, we provide a detailed examination of SHBs trafficking using biochemical approaches coupled with high-resolution confocal microscopy and live-cell imaging via a novel fluorophore-tagged SHBs probe in both HepG2 and primary human hepatocytes stably expressing SHBs. Our results provide evidence that SHBs utilize a modified ER-Golgi secretory pathway with transit from the ER to the multivesicular body and lysosomal/late endosomal compartments. Importantly, we identified the autophagy adapters ATG5 and LC3B, and the ER-phagy protein atlastin 3 (ATL3), central to mediating SHBs secretion. These findings suggest that SHBs is trafficked through a non-canonical path for secretion and provides new potential therapeutic targets for the treatment of CHB.